Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01907100 · ClinicalTrials.gov registry record · Phase 2
Nintedanib (BIBF 1120) in Mesothelioma
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 2
- Development phase
- 545
- Enrollment target
NCT01907100 is a Phase 2 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 545 participants.
The verdict
NCT01907100, a Phase 2 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 545 participants
- Enrollment target
Study Summary
This is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF 1120) versus placebo + pemetrexed / cisplatin followed by placebo for the treatment of patients with unresectable malignant pleural mesothelioma.
Interventions
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Nintedanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 545 participants |
| Start Date | 2013-09-19 |
| Est. Completion | 2018-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01907100
The ClinicalTrials.gov registry entry for NCT01907100 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 545 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT01907100 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01907100 about?
NCT01907100 is a clinical study titled "Nintedanib (BIBF 1120) in Mesothelioma". This is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF 1120) versus placebo + pemetrexed / cisplatin followed by placebo for the treatment of patients with unresectable ma...
What is the current status of trial NCT01907100?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 545 participants. The study started on 2013-09-19. Estimated completion is 2018-08-31.
What interventions are being tested in trial NCT01907100?
The interventions under investigation include: Cisplatin (DRUG), Pemetrexed (DRUG), Nintedanib (DRUG).
Who is sponsoring clinical trial NCT01907100?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.